NASHVILLE, Tenn., Nov. 9, 2022 /PRNewswire/ -- uMETHOD Health, a health technology company specializing in precision medicine for complex diseases, announces a partnership with PathGroup, one of largest independent laboratories in the United States. uMETHOD's AI-based care planning solution, RestoreU, pairs comprehensive testing from PathGroup with actionable treatment recommendations, aimed at lowering patient's risk of developing Alzheimer's and disease progression in its early stages. Read the full release.…READ MORE

uMETHOD Health is partnering with regional and national diagnostic laboratories and hundreds of physicians to identify and address the multiple factors that contribute to cognitive issues in seniors. The Raleigh, NC-based company produces leading-edge medical artificial intelligence (AI) and services to target complex diseases such as Alzheimer’s Disease (AD). On the 29th annual World Alzheimer’s Day, uMETHOD states there are multiple contributors involved in the progression of AD and they…READ MORE

uMETHOD Health is a technology company in Research Triangle Park, North Carolina, focused on treating the causes of com­plex diseases.  Its RestoreU METHOD uses patented artificial-intelligence (AI) software to identify the underlying factors that drive someone’s cognitive decline.  This software generates personalized care plans on how to prevent, slow, or even roll-back the progression of cognitive decline.  The software now identifies all the drugs someone may be taking that increase…READ MORE

Dr. Marwan Sabbagh, an Alzheimer’s disease expert and geriatric neurologist at the Barrow Institute in Phoenix, AZ joined Rob Sherman, product manager at Sonora Quest to discuss how the health care community can help combat the rapid rise of Alzheimer's disease in Arizona using progressive and innovative solutions like RestoreU, offered by uMETHOD Health and Sonora Quest Laboratories. The conversation highlights Dr. Sabbagh's use of RestoreU to improve diagnostic confidence…READ MORE

Most physicians can assess whether a patient is developing Alzheimer’s disease in five minutes, according to the Alzheimer’s Association. But few general practitioners include the screening in checkups, even though it’s covered as a yearly Medicare benefit. “Honestly, most doctors don’t want to find it,” says Tom Leggett, director of business development for Sonora Quest Laboratories in Tempe. “The uncomfortable truth is when you’re a physician and you find moderate…READ MORE